HEPATIC FIBROGENESIS INHIBITOR

摘要

PROBLEM TO BE SOLVED: To provide hepatic fibrogenesis inhibitors, therapeutic and/or prophylactic agents for diseases attributed to hepatic fibrogenesis, and the like, comprising components that have demonstrated to be excellent in safety or taste due to long history of use, the inhibitors, agents, and the like being ingestible for a long period of time.SOLUTION: We confirmed that hepatic fibrogenesis is inhibited in a rat administered with feed containing the protein of which 50% by weight is α-lactalbumin and 50% by weight is casein, as compared with a rat administered with feed containing the protein of which 100% by weight is casein, and that the increase of ALT (alanine amino transferase), AST (aspartic acid amino transferase), bilirubin total, and MMP (matrix metalloproteinase)-2 in serum that are indicators of hepatic cirrhosis is inhibited. From such findings, we found that hepatic fibrogenesis can be inhibited by administering α-lactalbumin, and also found the potential of the treatment and/or prevention of diseases attributed to hepatic fibrogenesis.SELECTED DRAWING: None